Abstract
ObjectiveTo describe the efficacy, safety, compliance and cost savings of lopinavir/ritonavir monotherapy. MethodObservational, descriptive and retrospective study evaluating monotherapy. Adherence was calculated using an objective method. We estimated the direct costs of dispensing non-triple therapy. ResultsWe identified 17 patients. Interval adherence was >95% in 9 patients, 90%–95% in 2 patients, 90%–85% in 2 patients, and less than 85% in 4 patients. Viral load was undetectable during weeks 12, 24, 36, and 48, except in 2 patients. The CD4 count in most analytical tests remained at >350cells/ml, only 1 patient had a lower figure. The average savings was 4819 Euros/patient/year (range 1116–8700). ConclusionsIn selected patients, monotherapy can be a cost-effective treatment option.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
